Answers are grounded in this paper and cite their sources.
Highlights•m6A reader YTHDF2 was highly expressed in pro-tumoral macrophages•YTHDF2 correlates with pro-tumoral and immuno-suppressing signals of macrophages•Identification of SPI1 as key transcriptional regulator in YTHDF2-high macrophage•Ythdf2 associates with pro-tumoral phenotype polarization of macrophages in the miceSummaryPatients with triple-negative breast cancer (TNBC) frequently experience resistance to chemotherapy, leading to recurrence. The approach of optimizing anti-tumoral immunological effect is promising in overcoming such resistance, given the heterogeneity and lack of biomarkers in TNBC. In this study, we focused on YTHDF2, an N6-methyladenosine (m6A) RNA-reader protein, in macrophages, one of the most abundant intra-tumoral immune cells. Using single-cell sequencing and ex vivo experiments, we discovered that YTHDF2 significantly promotes pro-tumoral phenotype polarization of macrophages and is closely associated with down-regulated antigen-presentation signaling to other immune cells in TNBC. The in vitro deprivation of YTHDF2 favors anti-tumoral effect. Expressions of multiple transcription factors, especially SPI1, were consistently observed in YTHDF2-high macrophages, providing potential therapeutic targets for new strategies. In conclusion, YTHDF2 in macrophages appears to promote pro-tumoral effects while suppressing immune activity, indicating the treatment targeting YTHDF2 or its transcription factors could be a promising strategy for chemoresistant TNBC.
No takes yet. Share an insight, caveat, or question.
Jin et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: